None listed
Conditions
Interventions
Group 1 Type of group
The doses will be calculated according to the levels of glycemia. Patients will be transferred from Regular Insulin + NPH Insulin to Humalog + Humulin N in equivalent amounts. The treatment will last 4 weeks.
Sponsors
ELI LILLY INTERAMERICA INC.,
Eligibility
Inclusion criteria
Inclusion criteria: Patients of both sexes diagnosed with Diabetes Mellitus type 1 or 2 who require insulin as defined by the WHO Diagnostic criteria (Annex S009-2) and who are already receiving Regular Insulin + NTH Insulin will be considered eligible to be enrolled in this program .
Exclusion criteria
Exclusion criteria: NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Fasting and postprandial blood glucose Measure:Change in the level of Blood Glucose Timepoints:4 and 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Measurement of HbA1 (glycosylated hemoglobin) Measure:Change in the levels of Glycosylated hemoglobin Timepoints:Week 0 and 8 ; Outcome name:A hypoglycemic episode is defined as any episode in which the patient feels, or another person observes, that he / she is experiencing a sign / symptom associated with hypoglycemia, or a blood glucose measurement less than 54 mg / dL. Measure:Appearance Hypoglycemic episodes Timepoints:Weeks 0, 4 and 8 ; Outcome name:Registry of adverse events Measure:Safety Timepoints:When the event happens | — |
Outcome results
None listed